Sunovion's Stedesa gets second chance at US FDA
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review Sunovion Pharmaceuticals' new drug application for Stedesa (eslicarbazepine acetate), an investigational voltage-gated sodium and T-type calcium channel blocker, for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years or older with epilepsy.